Evidence map›Paper›PMID 41727552›Full record

ArticleFrontiers in pharmacology2026

Components of

Ming Yao, Xiaoli Wang, Hongyu Wei, Lisha Wang, Dongze Zhang, Zheng Liang, Rong He, Yuan He, Lihong Jiang, Yingzi Cui

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ming YaoDepartment of Cardiovascular Medicine, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Xiaoli WangDepartment of Cardiovascular Medicine, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Hongyu WeiDepartment of Cardiovascular Medicine, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Lisha WangCollege of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Dongze ZhangDepartment of Cardiovascular Medicine, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Zheng LiangCollege of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Rong HeCollege of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Yuan HeCollege of Rehabilitation Medicine, Changchun University of Chinese Medicine, Changchun, China.
Lihong JiangDepartment of Cardiovascular Medicine, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Yingzi CuiDepartment of Cardiovascular Medicine, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The combination of ginsenoside Rg1 and salidroside (PRC) exhibits cardioprotective potential against myocardial ischemia-reperfusion injury (MIRI), yet its underlying mechanism remains unclear. Materials and Methods: An Results: PRC reduced infarct size, ameliorated mitochondrial ultrastructure, and attenuated oxidative stress Conclusion: PRC attenuates MIRI by activating the SIRT1/3-PGC-1α-NRF2 pathway to modulate PINK1/Parkin-dependent mitophagy, thereby restoring mitochondrial homeostasis. Our study elucidates a novel mechanism underlying this natural product combination and highlights the SIRT1/3 axis as a promising therapeutic target for cardioprotection.

Indexed as

ginsenoside Rg1mitochondrial functionmitophagymyocardial ischemia-reperfusion injurysalidroside

Identifiers

PMID41727552
PMCPMC12920564

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.